These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19055588)

  • 1. Who's minding the data? Data Monitoring Committees in clinical cancer trials.
    Keating P; Cambrosio A
    Sociol Health Illn; 2009 Apr; 31(3):325-42. PubMed ID: 19055588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring clinical trials: issues and controversies regarding confidentiality.
    Fleming TR; Ellenberg S; DeMets DL
    Stat Med; 2002 Oct; 21(19):2843-51. PubMed ID: 12325100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data monitoring committees: the moral case for maximum feasible independence.
    Walters L
    Stat Med; 1993 Mar; 12(5-6):575-80; discussion 581-2. PubMed ID: 8493433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 17. Small sample approach, and statistical and epidemiological aspects.
    Offringa M; van der Lee H
    Handb Exp Pharmacol; 2011; 205():181-202. PubMed ID: 21882112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues in regulatory guidelines for data monitoring committees.
    DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
    Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study.
    Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D
    PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.